FindTrial
Sign In

The Study of the Validation of General Evaluation Score (GES) in the Prediction of Hepatocellular Carcinoma Risk Among Patients With Advanced Fibrosis and Cirrhosis Who Achieved Sustained Virological Response for Hepatitis C Virus After Direct Acting Antiviral Drugs

The Study of the Validation of General Evaluation Score (GES) in the Prediction of Hepatocellular Carcinoma Risk Among Patients With Advanced Fibrosis and Cirrhosis Who Achieved Sustained Virological Response for Hepatitis C Virus After Direct Acting Antiviral Drugs

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06325826
Enrollment
500
Registered
2024-03-22
Start date
2022-02-01
Completion date
2025-06-30
Last updated
2024-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Brief summary

This cohort study aims to evaluate the validation of general evaluation score in the prediction of hepatocellular carcinoma risk among patients with advanced fibrosis (F3) and cirrhosis (F4) who achieved sustained virological response for hepatitis c virus after direct acting antiviral drugs and determine the group of these patients who require intensified surveillance.

Interventions

DIAGNOSTIC_TESTGeneral Evaluation Score (GES)

According to Evaluation of GES scores Patient will be classified into three groups based on GES score low risk group (score ≤6 points), intermediate risk group (score 6-7.5 points), and high-risk group (score \>7.5 points)

Sponsors

Egyptian Liver Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients aged 18 years or older. * Patients with compensated advanced chronic liver disease (cACLD) according to Baveno VI consensus (F3-F4) * achieved SVR for HCV after DAAs.

Exclusion criteria

* Previous interferon (IFN) treatment. * Hepatitis B virus (HBV) or human immune-deficiency virus (HIV) co-infection. * Current hepatocellular carcinoma (HCC) or other malignancies. * Previous history of HCC or HCC intervention. * Liver cell failure, liver transplantation or renal impairment

Design outcomes

Primary

MeasureTime frameDescription
Hepatocellular Carcinoma24 monthNumber of Participants develop New Hepatocellular Carcinoma

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026